Antibodies News and Research

RSS
New type of immunotherapy shows promise for advanced skin cancer

New type of immunotherapy shows promise for advanced skin cancer

Test sites quickly attract thousands for COVID-19 vaccine study

Test sites quickly attract thousands for COVID-19 vaccine study

Nanoparticle method captures and measures common marker of heart disease

Nanoparticle method captures and measures common marker of heart disease

Immune system derails during severe course of COVID-19

Immune system derails during severe course of COVID-19

New alpha-radioimmunotherapy for multiple myeloma shows promise in preclinical study

New alpha-radioimmunotherapy for multiple myeloma shows promise in preclinical study

America’s obesity epidemic threatens effectiveness of any COVID vaccine

America’s obesity epidemic threatens effectiveness of any COVID vaccine

Carefully engineered spike protein can help develop COVID-19 vaccine

Carefully engineered spike protein can help develop COVID-19 vaccine

Cats susceptible to and potential reservoirs for novel coronavirus

Cats susceptible to and potential reservoirs for novel coronavirus

A SARS-CoV-2 assay using plant proteins

A SARS-CoV-2 assay using plant proteins

NIH-Moderna investigational vaccine protects mice from infection with SARS-CoV-2

NIH-Moderna investigational vaccine protects mice from infection with SARS-CoV-2

Evidence for antibody longevity in COVID-19 patients

Evidence for antibody longevity in COVID-19 patients

New serological test for COVID-19 helps determine herd immunity, vaccine efficacy

New serological test for COVID-19 helps determine herd immunity, vaccine efficacy

Beneficial microbes reprogram the B cell repertoire that produce antibodies

Beneficial microbes reprogram the B cell repertoire that produce antibodies

Study provides comprehensive update on ACE2 enzyme with key role in SARS-CoV-2 infection

Study provides comprehensive update on ACE2 enzyme with key role in SARS-CoV-2 infection

Laboratory test shows only 60% of COVID-19 patients develop protective antibodies

Laboratory test shows only 60% of COVID-19 patients develop protective antibodies

Avidity of binding responsible for cross-neutralization of SARS-CoV-1 and SARS-CoV-2

Avidity of binding responsible for cross-neutralization of SARS-CoV-1 and SARS-CoV-2

Potential antibody treatment for yellow fever developed in 7 months using Rapid Response Strategy

Potential antibody treatment for yellow fever developed in 7 months using Rapid Response Strategy

Regeneron's COVID-19 antibody-drug cocktail treats SARS-CoV-2 virus in animals

Regeneron's COVID-19 antibody-drug cocktail treats SARS-CoV-2 virus in animals

De novo protein decoys that block SARS-CoV-2

De novo protein decoys that block SARS-CoV-2

ACTG initiates novel clinical trial to evaluate multiple therapeutics for COVID-19

ACTG initiates novel clinical trial to evaluate multiple therapeutics for COVID-19

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.